Vical
San Diego
About Vical
Vical's core technology grew out of a chance discovery and provided the cornerstones for two new biopharmaceutical industry sectors: DNA vaccines and non-viral gene therapy. Vical's management systematically leveraged that technology into a broad portfolio of independent and partnered product development programs. The first products for animal health are on the market. The first human products are approaching.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 251 – 500
- Total funding: $111.3M
- Funding stage: M&A
- Last round: Post-IPO Equity (Nov 2017)
- Ticker: nasdaq:VICL
- Website: vical.com
- Phone: 8586461104
Industries & Categories
Biotechnology, Genetics
Social Profiles
Canonical: https://fsome.com/organization/vical-102642 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.